OrbiMed, 5AM Ventures, Frazier, and Aisling at 9th Anti-infectives Partnering Conference July 9 2012
Joseph Larsen, Chief of Broad Spectrum Antimicrobials (BSA) Program and Division of CBRN Countermeasures at DHHS / ASPR / BARDA will give a featured presentation about Partnering and Working with BARDA at the 9th Anti-Infectives Partnering and Deal-making Conference taking place on July 9-10, 2012 in San Francisco, CA.
- (1888PressRelease) May 09, 2012 - OrbiMed Advisors, 5AM Ventures, Frazier Healthcare, and Aisling Capital will discuss "Investment Opportunities with Venture Capitalists" at the 9th Anti-Infectives Partnering and Deal-making Conference taking place on July 9-10, 2012 in San Francisco, CA.
Representatives from each group will come together on a panel discussion to discuss:
• Attractiveness of anti-infectives from a VC perspective:
- The relatively strong translation of preclinical data to clinical POC w/ anti-infectives
- Relatively short time-frames to demonstrate efficacy, although regulatory bar is different depending on indications.
- Pharma has substantially move out of ID, therefore making this the best time to invest for when appetite strengthens and pipelines are thin.
• Challenges from a VC perspective:
- Regulatory challenges remain significant, despite language towards a more personalized therapy approach.
- Pricing-the culture of commodity pricing for antibiotics is entrenched, although we are seeing strong examples recently that is moving towards "value-based" pricing. This will be critical.
• Areas they are watching.
GTC's 9th Anti-infectives Partnering and Deal-Making Conference will contribute to the on-going battle against the ever-changing infectious threats by having experts with direct experiences in the field discuss a wide variety of topics on infectious diseases. The agenda also allows time for networking and opportunities to interface with speakers and fellow delegates in a collegial setting. Previous GTC conferences have been catalytic to several successful partnerships and in 2012 we expect this trend to continue.
For more information, please visit www.gtcbio.com